Pryor Cashman represented Marina Biotech, Inc. (OTCQB: MRNA) in connection with the private placement of $1.1 million of Series D Convertible Preferred Stock and warrants to purchase common stock to existing investors.  The offering closed on August 7, 2015.  Marina Biotech, Inc. is a leading nucleic acid-based drug discovery and development company focused on rare diseases.

Partner Lawrence Remmel, Chair of Pryor Cashman’s Banking & Finance Group, and Counsel Michael T. Campoli , a member of the firm’s Corporate Group, represented Marina Biotech in the transaction.

The transaction was reported in the August 6, 2015 issue of The Deal. To read the article, please click here.